BioSpace News Archive

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the FDA clearance of the AcQCross™ family of universal transseptal crossing devices.

Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company.

Nasus Pharma Ltd, a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal specialized product portfolio to address acute medical conditions & public health threats, announced positive results from a pivotal trial of intranasal powder-based Naloxone.

Incyte announced that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 4, 2021.

LintonPharm Co., Ltd. announced that China’s health authority, National Medical Products Administration authorized the company to proceed with a Phase 1/2 clinical trial evaluating the safety and efficacy of catumaxomab in patients with Non-Muscle-Invasive Bladder Cancer whose tumors have recurred due to Bacillus Calmette-Guerin vaccine failure.

MultiPulse Therapy™ (MPT™) achieved 71% termination of acute, induced atrial fibrillation (AF) episodes at energy levels deemed to be tolerable for patients

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with ChemGenes Corporation, a biotechnology company providing unparalleled expertise in the field of DNA/RNA synthesis for more than 40 years.

Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp., announced that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief Strategic Officer, Nancy Duitch will headline Collision 2021.

Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver Senti Bio is potentially eligible to receive upfront, opt-in and milestone payments exceeding $645 million

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29 , at 4:30 p.m. ET to discuss first quarter 2021 financial results and provide a general business update.